当前位置：   首页 > 需求大厅

 >  生产研发 

需要完整的甲苯磺酸妥舒沙星中试（公斤级）工艺；完整工艺杂质研究、初步的质控标准。   [更多]

头孢克肟的每一组份的国家标准及国标里的检测方法，所用的仪器等 国标内容给我就可以   [更多]

我单位现需要这份标准，但已经咨询过国家药监局、及省局仍然没有找到！希望可以知道在哪可以购买   [更多]

品种1：抗肿瘤类，50ml西林瓶 品种2：抗生素类，5ml西林瓶 品种3：抗生素类，10ml西林瓶 以上3个品种均为冻干粉针，我公司需要寻找冻干车间，制备3批中试样品（3批注册批），主要服务是提供中试生产场地及协助我们进行中试3批生产。希望能提供服务的公司与我联系，服务价格我预估在10万左右（每个品种10万，只是我个人预估的），实际成交价格可以面谈。   [更多]

招募急性痛风性关节炎志愿者 招募概述： 如果您是急性痛风性关节炎患者，符合以下条件就可以报名参加虎贞痛风胶囊的临床研究。虎贞痛风胶囊由广东一力集团制药有限公司/广州暨南生物医药研究开发基地有限公司研制并提供的，并于2008年经国家食品药品监督管理局批准进行临床研究，临床试验批件号：2008L02043。其具有清热利湿，化瘀利浊，滋补肝肾的功效。主治急性痛风性关节炎（湿热蕴结证），症见：关节红肿热痛，伴有发热，汗出不解，口渴喜饮，心烦不安，小便黄及痛风病见上述症候者。此研究由中国中医科学院广安门医院等15家医院共同参与。 如果您愿意参加本项研究并通过筛选符合条件，我们将为您提供3天的免费治疗并免费进行相关检查（包含：体格检查、血常规、尿常规、便常规、肝肾功、心电图、血尿酸、类风湿因子、血沉、C反应蛋白和抗链球菌溶血素‘O’）。 入选条件： 1.符合急性痛风性关节炎诊断标准，且辨证为湿热蕴结证。 2.急性发作在48小时之内，本次发作未用过治疗药（包括秋水仙碱、非甾类抗炎药及激素等）者。 3.VAS评分≥4分。 4.年龄18-65岁。 5.签署知情同意书。 您一旦参加本试验将获得较全面的检查和试验药物治疗，并将得到医生的全面跟踪随访。 如您符合纳入标准，并有意参加本研究项目，请到辽宁中医药大学第二附属医院住院部A楼三楼糖尿病科咨询 。 地址：沈阳市皇姑区黄河北大街60号 联系方式：江红主任：138 4008 4568 马尧医生：139 4046 6290   [更多]

日本住友药业的注射用美罗培南说明书，要CFDA今年批准修订的最新版本的。   [更多]

在合理合法的范围内   [更多]

成本，生产周期，产品质量，工艺规模请列出。   [更多]

设备应能至少每分钟测量血含量两次，连续测量时间至少60分钟。探头小巧并方便弯曲，准确度：设备必须能够衡量的范围为0 - 1.25毫升的血（稀释在大约15 - 30毫升的盐水中），精度要测准大约6µl的血（稀释在大约15 - 30毫升的盐水中）。 具体如下：https://www.innocentive.com/ar/challenge/9933690 The Seeker desires a device to continuously and/or repeatedly measure the amount of blood in a volume of saline. The device should be capable of measuring at least twice per minute for at least 60 minutes. This is a Reduction-to-Practice Challenge that requires a written proposal, experimental proof-of-concept data, and prototype delivery if requested Source: InnoCentive Challenge ID: 9933690 Challenge Overview The Seeker is looking for a device to continuously measure blood content in a small volume of saline. Blood is introduced continuously through a thin, flexible probe placed in the container of saline and the device must be able to measure the overall blood content in the container at least twice per minute for at least 60 minutes. The device must be able to measure over the range of 0 – 1.25 ml of blood in approximately 15 – 30 ml of saline with an accuracy of approximately 6 µl of blood. Only minimal stirring is allowed, thus devices should not rely on an assumption of uniform mixing of the blood in the saline solution. The rate of blood introduction may vary significantly, and may start and stop numerous times. The submission to the Challenge should include the following: The detailed description of the proposed Solution addressing specific Solution Requirements presented in the Detailed Description of the Challenge. This description should be accompanied by a well-articulated rationale supported by literature/patent precedents. Experimental proof-of-concept data obtained as outlined in the Detailed Description of the Challenge (and delivery of a prototype if requested by the Seeker).   [更多]

罕见癌症研究基金会(RCRF),致力于通过战略投资和创新合作进行基础治疗罕见的癌症,和美国文化募捐组织(ATCC),世界上最大的非营利性细胞株库,建立神经内分泌肿瘤细胞株收集目录。肠道良性肿瘤和胰腺神经内分泌肿瘤(PNET)需求一种新疗法的研究和发展，即在体内原发性肿瘤中建立新的细胞株。 为了刺激发展新的良性肿瘤和PNET细胞系,该基金会是高兴地宣布第二次开放竞争十个人奖项:开发人员的第一个新的细胞系在每个疾病(肠道良性肿瘤和PNET)将获得100000美元，开发者的第二,第三,第四,第五个新细胞系在每个疾病将会收到50000美元。原文如下：https://www.innocentive.com/ar/challenge/9933756 The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Caring for Carcinoid Foundation therefore wishes to launch a second Challenge to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog. This is a Reduction-to-Practice Challenge that requires written documentation, detailed description of each cell line, and sample delivery. Source: InnoCentive Challenge ID: 9933756 Challenge Overview This Challenge is intended to encourage innovative approaches to establishing new cell lines from primary tumors that grow slowly in vivo and to publicize new methods as well as availability of the new cell lines for broad, unrestricted use. To stimulate development of new carcinoid and PNET cell lines, the Foundation is pleased to announce its second open competition for up to ten individual prizes: Developers of the first new cell lines in each disease (intestinal carcinoid and PNET) will receive $100,000 each and developers of the second, third, fourth, and fifth new cell lines in each disease will receive $50,000 each. Individual   [更多]